Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $61.29 USD
Change Today -1.16 / -1.86%
Volume 174.7K
ANIP On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

ani pharmaceuticals inc (ANIP) Snapshot

Open
$62.24
Previous Close
$62.45
Day High
$62.79
Day Low
$60.80
52 Week High
04/23/15 - $72.61
52 Week Low
10/15/14 - $24.24
Market Cap
700.3M
Average Volume 10 Days
307.2K
EPS TTM
$2.58
Shares Outstanding
11.4M
EX-Date
--
P/E TM
23.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANI PHARMACEUTICALS INC (ANIP)

Related News

No related news articles were found.

ani pharmaceuticals inc (ANIP) Related Businessweek News

No Related Businessweek News Found

ani pharmaceuticals inc (ANIP) Details

ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products. The company’s targeted areas of product development include narcotics, oncolytics, hormones, and steroids, as well as complex formulations, such as extended release and combination products. Its products include Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema and Cortenema for the treatment of ulcerative colitis; and Metoclopramide and Reglan for treating gastroesophageal reflux. The company’s products also comprise Opium Tincture to treat diarrhea by slowing the movement of the intestines, and decreasing the number and frequency of bowel movements; Lithobid for treating the manic episodes of bipolar disorder; and Vancocin to treat difficile-associated diarrhea. In addition, it provides contract manufacturing services for various branded and generic companies. The company markets and sells its products through wholesalers, retail market chains, distributors and mail order pharmacies, and hospitals. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

92 Employees
Last Reported Date: 02/23/15

ani pharmaceuticals inc (ANIP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $461.5K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $303.1K
Vice President of Operations
Total Annual Compensation: $131.4K
Vice President of New Business Development & ...
Total Annual Compensation: $259.2K
Compensation as of Fiscal Year 2014.

ani pharmaceuticals inc (ANIP) Key Developments

ANI Pharmaceuticals, Inc. Announces FDA Approval of Oxycodone Hydrochloride Oral Solution 5mg/5mL

ANI Pharmaceuticals, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Oral Solution 5mg/5mL. Oxycodone Hydrochloride Oral Solution 5mg/5mL is an opioid agonist indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.

ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

ANI Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of $18.8 million against $10.9 million a year ago. Adjusted non- GAAP EBITDA was $11.5 million against $4.2 million a year ago. Operating income was $9.567 million against $3.495 million a year ago. The company provided earnings guidance for the year 2015. For the year, the company expects net revenues of $80 million to $88 million; adjusted non- GAAP EBITDA of $48.8 million to $53.0 million; and adjusted non-GAAP diluted earnings per share of $2.44 to $2.67.

ANI Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Re-Affirms Earnings Guidance for the Year 2015

ANI Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net revenues of USD 18.799 million compared to USD 10.899 million a year ago. Operating income was USD 9.567 million compared to USD 3.495 million a year ago. Income before income tax provision was USD 6.910 million compared to USD 3.524 million a year ago. Net income was USD 4.369 million compared to USD 3.359 million a year ago. Diluted earnings per share was USD 0.38 compared to USD 0.33 a year ago. Adjusted EBITDA was USD 11.462 million compared to USD 4.245 million a year ago. Diluted earnings per share were USD 0.57. The company generated USD 1.1 million of positive cash flows from operations in the first quarter ended March 31, 2015. The company re-affirmed earnings guidance for the year 2015. For the year, the company expected net revenues estimated to be between USD 80 million and USD 88 million. The company expected adjusted non-GAAP EBITDA, which excludes non-cash stock compensation expense, estimated to be between USD 48.8 million and USD 53.1 million. The company expected total interest expense of approximately USD 11.2 million. This includes cash interest expense of approximately USD 4.3 million and non-cash interest expense of approximately USD 6.9 million. The company estimated effective tax rate of approximately 36.8%. The company expected adjusted non-GAAP diluted earnings per share, which excludes non-cash stock compensation and non-cash interest expense, estimated to be between USD 2.44 and USD 2.67, assuming 11,561,635 weighted average shares outstanding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANIP:US $61.29 USD -1.16

ANIP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $307.51 USD +0.60
Glenmark Pharmaceuticals Ltd 1,019 INR -0.20
Lannett Co Inc $57.98 USD -0.67
Mylan NV $70.12 USD +0.42
View Industry Companies
 

Industry Analysis

ANIP

Industry Average

Valuation ANIP Industry Range
Price/Earnings 23.7x
Price/Sales 10.9x
Price/Book 4.8x
Price/Cash Flow 20.4x
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANI PHARMACEUTICALS INC, please visit www.anipharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.